vimarsana.com
Home
Live Updates
Intercept Announces New Data Showing Potential of Fixed-Dose
Intercept Announces New Data Showing Potential of Fixed-Dose
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,... | June 7, 2023
Related Keywords
United States ,
Vienna ,
Wien ,
Austria ,
Antonio Civitarese ,
Karen Preble ,
Frederik Nevens ,
Alexandre Louvet ,
Lynda Szczech ,
Nareg Sagherian ,
M Michelle Berrey ,
Cheng Zou ,
Vaclav Hejda ,
Research Development ,
Linkedin ,
Globenewswire Inc ,
Company On Twitter ,
Intercept Pharmaceuticals Inc ,
European Association For The Study ,
Nasdaq ,
Global Corporate Communications ,
International Normalized Ratio ,
Michelle Berrey ,
Chief Medical Officer ,
Planned Interim Analysis ,
Active Controlled Trial Evaluating ,
Obeticholic Acid ,
Serum Biomarkers ,
Primary Biliary ,
Bezafibrate Fixed Dose ,
Important Safety Information ,
Narrow Therapeutic ,
Bile Salt Efflux ,
Full Prescribing Information ,
Intercept Pharmaceuticals ,
Executive Director ,
Global Investor ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Interim ,
Analysis ,
F ,
Ngoing ,
Hase ,
,
Study ,
Shows ,
Combination ,
Ca ,
G ,
Bezafibrate ,
00 ,
Mproved ,
Levels ,
Multiple ,
Biochemical ,
Markers ,
Ssociated ,
Ith ,
Linical ,
Outcomes ,
N ,
Abc ,
Ncluding Icpt Us45845p1084 ,